Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice

dc.contributor.author	Butrón Bris, B.
dc.contributor.author	Llamas Velasco, M.
dc.contributor.author	Ovejero Benito, M. C.
dc.contributor.author	Santos-Juanes Jiménez, Jorge
dc.contributor.author	(et al.)
dc.date.accessioned	2025-02-07T07:21:52Z
dc.date.available	2025-02-07T07:21:52Z
dc.date.issued	2024
dc.identifier.citation	ExperiMental Dermatology, 33(8), (2024); doi:10.1111/exd.15152
dc.identifier.issn	0906-6705
dc.identifier.uri	https://hdl.handle.net/10651/76761
dc.description.sponsorship	Instituto de Salud Carlos III (ISCIII) [PI21/01583]; European Regional Development Fund; Almirall
dc.language.iso	eng
dc.relation.ispartof	ExperiMental Dermatology
dc.rights	©,
dc.source	Scopus
dc.source.uri	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85200057045&doi=10.1111%2fexd.15152&partnerID=40&md5=4b3e6e30faa9ebd11bb25d1ab6380cae
dc.title	Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice
dc.type	journal article
dc.identifier.doi	10.1111/exd.15152
dc.relation.publisherversion	http://dx.doi.org/10.1111/exd.15152

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.